These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. Medves S; Noël LA; Montano-Almendras CP; Albu RI; Schoemans H; Constantinescu SN; Demoulin JB Haematologica; 2011 Oct; 96(10):1406-14. PubMed ID: 21685469 [TBL] [Abstract][Full Text] [Related]
47. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm. Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256 [TBL] [Abstract][Full Text] [Related]
48. Enhancer of Polycomb and the Tip60 complex repress hematological tumor initiation by negatively regulating JAK/STAT pathway activity. Bailetti AA; Negrón-Piñeiro LJ; Dhruva V; Harsh S; Lu S; Bosula A; Bach EA Dis Model Mech; 2019 May; 12(5):. PubMed ID: 31072879 [TBL] [Abstract][Full Text] [Related]
49. Truncated RUNX1 protein generated by a novel t(1;21)(p32;q22) chromosomal translocation impairs the proliferation and differentiation of human hematopoietic progenitors. Rodriguez-Perales S; Torres-Ruiz R; Suela J; Acquadro F; Martin MC; Yebra E; Ramirez JC; Alvarez S; Cigudosa JC Oncogene; 2016 Jan; 35(1):125-34. PubMed ID: 25798834 [TBL] [Abstract][Full Text] [Related]
50. Fadd and Skp2 are possible downstream targets of RUNX1-EVI1. Maki K; Sugita F; Nakamura Y; Sasaki K; Mitani K Int J Hematol; 2013 Jan; 97(1):83-91. PubMed ID: 23250858 [TBL] [Abstract][Full Text] [Related]
51. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Ho JM; Beattie BK; Squire JA; Frank DA; Barber DL Blood; 1999 Jun; 93(12):4354-64. PubMed ID: 10361134 [TBL] [Abstract][Full Text] [Related]
52. Histone Chaperone HIRA in Regulation of Transcription Factor RUNX1. Majumder A; Syed KM; Joseph S; Scambler PJ; Dutta D J Biol Chem; 2015 May; 290(21):13053-63. PubMed ID: 25847244 [TBL] [Abstract][Full Text] [Related]
53. Rare and novel RUNX1 fusions in myeloid neoplasms: A single-institute experience. Aypar U; Yao J; Londono DM; Khoobyar R; Scalise A; Arcila ME; Roshal M; Xiao W; Zhang Y Genes Chromosomes Cancer; 2021 Feb; 60(2):100-107. PubMed ID: 33078873 [TBL] [Abstract][Full Text] [Related]
54. ETV6-RUNX1-positive ALL may be driven by aberrant RAG activity. Cancer Discov; 2014 Mar; 4(3):OF15. PubMed ID: 24596209 [TBL] [Abstract][Full Text] [Related]
55. Clonal origins of ETV6-RUNX1⁺ acute lymphoblastic leukemia: studies in monozygotic twins. Alpar D; Wren D; Ermini L; Mansur MB; van Delft FW; Bateman CM; Titley I; Kearney L; Szczepanski T; Gonzalez D; Ford AM; Potter NE; Greaves M Leukemia; 2015 Apr; 29(4):839-46. PubMed ID: 25388957 [TBL] [Abstract][Full Text] [Related]
56. Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis. Wang Z; Medrzycki M; Bunting ST; Bunting KD Oncotarget; 2015 Oct; 6(30):28961-72. PubMed ID: 26338970 [TBL] [Abstract][Full Text] [Related]
57. Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. Antony-Debré I; Manchev VT; Balayn N; Bluteau D; Tomowiak C; Legrand C; Langlois T; Bawa O; Tosca L; Tachdjian G; Leheup B; Debili N; Plo I; Mills JA; French DL; Weiss MJ; Solary E; Favier R; Vainchenker W; Raslova H Blood; 2015 Feb; 125(6):930-40. PubMed ID: 25490895 [TBL] [Abstract][Full Text] [Related]
58. ETV6-RUNX1 interacts with a region in SPIB intron 1 to regulate gene expression in pre-B-cell acute lymphoblastic leukemia. Xu LS; Francis A; Turkistany S; Shukla D; Wong A; Batista CR; DeKoter RP Exp Hematol; 2019 May; 73():50-63.e2. PubMed ID: 30986496 [TBL] [Abstract][Full Text] [Related]
59. Gatekeeper function of the RUNX1 transcription factor in acute leukemia. Niebuhr B; Fischer M; Täger M; Cammenga J; Stocking C Blood Cells Mol Dis; 2008; 40(2):211-8. PubMed ID: 17920312 [TBL] [Abstract][Full Text] [Related]
60. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms. Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]